- Home
- / CytomX Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
CytomX Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1
2024-10-29
Market Capitalization
$78 M
2024-10-29
Revenue
$138.1 M
FY, 2024
CreditSafe Score
?
Score changed on Jul 08, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.7M | 15.0M | 71.6M | 59.5M | 57.5M | 100.4M | 69.6M | 53.2M | 101.2M | 138.1M |
| Revenue growth, % | 95.1% | |||||||||
| General and administrative expense | 12.6M | 19.9M | 25.6M | 33.5M | 36.8M | 36.0M | 39.2M | 30.0M | 29.7M | |
| Operating expense total | 40.9M | 74.6M | 117.9M | 137.4M | 168.4M | 149.0M | 113.1M | |||
| EBIT | (33.2M) | (59.6M) | (46.3M) | (77.9M) | (110.9M) | (48.6M) | (83.8M) | (6.5M) | 25.0M | |
| EBIT margin, % | -430.5% | -396.1% | -64.6% | -130.9% | -192.9% | -48.4% | 18.1% | |||
| Interest income | 1.3M | 2.4M | 2.7M | 7.6M | 8.4M | 1.8M | 255.0K | 9.8M | 7.1M | |
| Pre tax profit | (35.4M) | (58.9M) | (43.6M) | (70.3M) | (102.7M) | (46.8M) | (83.6M) | (99.3M) | 3.3M | 32.1M |
| Income tax expense | 10.0K | (19.0K) | (513.0K) | 14.3M | (427.0K) | (13.9M) | 3.9M | 224.0K | ||
| Net Income | (35.4M) | (58.9M) | (43.1M) | (84.6M) | (102.2M) | (32.9M) | (83.6M) | (569.0K) | 31.9M |